Humanisierter anti-CCR2 Antikörper zur Therapie von MS und RA
Regensburg haben gemeinsam einen anti-CCR2 Antikörper zur Therapie von Multipler Sklerose (MS) und Rheumatoider Arthritis (RA) entwickelt. Der Spitzenantikörper wurde in Kooperation mit dem MRC Technologies humanisiert. Er bindet CCR2 Rezeptoren und moduliert die Immunantwort durch die Depletierung von CCR2+ Monozyten.
Scientists of the University of Göttingen and of the University of Regensburg developed in collaboration a proprietary anti-CCR2 antibodies for the therapy of Multiple Sclerosis (MS) and potentially Rheumatoid Arthritis (RA). The lead candidate Doc-2 has been humanized in collaboration with the MRC Technologies. It targets the CCR2 receptor and modulates the autoimmune process through depletion of CCR2+ monocytes.
We achieved successful in vivo Proof of Principle with primates (marmoset), showing improvement of clinical score, good plasma levels of the humanized Doc-2 antibody, a sustained depletion of CCR2+ monocytes and no undesired side effects.
Bilder & Videos
Multiple sclerosis (MS) is a chronic demyelinating disease of CNS of unkown etiology. MS destroys mainly the myelin layer which normally protects nerve fibres and helps them to conduct electrical impulses. MS involves repeated episodes of inflammation of nervous tissue. This damage decreases transmission of messages leading to diminished or lost function. High dose steroids/ glucocorticoids in acute MS does not show improvement of MS symptoms in 40% of patients.
Worldwide it is estimated that there are > 1 million cases suffering from Multiple Sclerosis (MS). The world market for MS is estimated to be 3.0 billion US$ corresponding to an annual growth rate of 20%, making it one of the fastest growing CNS therapy areas. The prevalence of MS varies widely by geographic region, achieving up to 170 per 100.000 in the UK. Key countries are UK, Germany and U.S.A..
We offer a proprietary humanized anti-CCR2 antibody (DOC-2) for the therapy of Multiple Sclerosis (MS), acute exacerbations of MS, Rheumatoid Arthritis (RA), and potentially further diseases where CCR2 plays a pivotal roll. These antibody recognizes and binds to a 3D epitope in the loops of CCR2 and modulates the autoimmune process.
- Successful "proof of principle" in primates (EAE marmoset model).
- Significant Improvement of clinical score.
- Sustained depletion of CCR2+ monocytes.
- Very good plasma levels of humanized Doc-2 antibodies in marmoset.
- No undesired side effects observed.
- Depletion of CCR2+ monocytes by Fc-receptor mediated ADCC.
- The targeted CCR2 Receptor is linked to neurological inflammatory diseases.
- Humanization of anti-CCR2 antibody through collaboration with the Medical Research Council Technology, MRCT.
These anti-CCR2 antibody is being developed for ther therapy of Multiple Sclerosis (MS), acute exacerbations of MS, Rheumatoid Arthritis (RA), and potentially other diseases, where CCR2 plays a roll, like e.g. DSS collitis, intracerebral hemorrhage, lung injury, vascular injury, myocardial infarction.. The future treatment of MS will be less focused on beta interferon injections and opens the door to novel therapies. Novel therapy areas offer specialty pharmas a niche in which to compete.
- EP EP2004692B1 erteilt
- US US9068002 erteilt
- CA CA2648330 erteilt
StichworteMBM ScienceBridge GmbH, Technologieangebot/technology offer, Technologietransfer/ technology transfer, Georg-August-Universität , Univeristät Regensburg Göttingen, antikörper, therapie, multiple sklerose, rheuma, rheumatoide arthritis, ccr2, antibody, therapy, multiple sclerosis, rheumatoid arthritis, ccr2